ConcertAI Stock

concertai.comHealthcare / Healthcare softwareFounded: 2017

ConcertAI is a provider of healthcare enterprise AI and data-powered SaaS solutions.

Register To Buy and Sell Shares

For more details on financing and valuation for ConcertAI, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access ConcertAI’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ConcertAI.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About ConcertAI’s Stock

Can you buy ConcertAI’s stock?
ConcertAI is not publicly traded on NYSE or NASDAQ in the U.S. To buy ConcertAI’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell ConcertAI’s stock?
Yes, you can sell stock of a private company like ConcertAI. Forge can help you sell your ConcertAI stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is ConcertAI’s stock price?
ConcertAI is a privately held company and therefore does not have a public stock price. However, you may access ConcertAI’s private market stock price with Forge Data.
What is ConcertAI’s stock ticker symbol?
ConcertAI does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

After more than a decade, ASCO sells CancerLinQ to ConcertAI
ConcertAI, a company specialising in real-world evidence and generative AI, has purchased CancerLinQ, a real-world data and quality of care technology service from the American Society of Clinical Oncology. ConcertAI plans to invest $250 million in cancer informatics as part of the acquisition of CancerLinQ, which includes a network of over 100 cancer centres and oncology practices, as well as around seven million patient records.
QuantHealth hires former ConcertAI, Allscripts leader and more digital health hires
QuantHealth, an Israeli AI-enabled clinical trial-design startup, has appointed David Dornstreich as its general manager and chief commercial officer of U.S. operations. Dornstreich will help scale QuantHealth's business globally and oversee its U.S. operations. The healthcare veteran previously held senior roles at ConcertAI, Allscripts, and Dr. Evidence.
Caris Life Sciences and ConcertAI Announce New Clinico-Genomic Research Platform
Caris Life Sciences and ConcertAI have announced an expanded partnership for clinical development solutions, aimed at improving patient care for those with cancer. The partnership will create a prospectively generated, electronic health record-enabled, and contemporaneously matched database of molecular, clinical and multi-modal data. This will enable novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
Updated on: Jun 16, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.